LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.

LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.

Classical Parkinson's disease (PD) is characterized by the appearance of Lewy bodies (LBs) in affected brain regions, showing mostly compact alpha-synuclein deposition, in contrast with punctate or granular deposition, hypothesized to represent early stages of aggregation. Leucine-rich repeat k...

Full description

Bibliographic Details
Main Authors:	Alegre-Abarrategui, J, Ansorge, O, Esiri, M, Wade-Martins, R
Format:	Journal article
Language:	English
Published:	2008

Similar Items

Parkinson disease, LRRK2 and the endocytic-autophagic pathway.
by: Alegre-Abarrategui, J, et al.
Published: (2009)

Relationship of Apolipoprotein E to Parkinson's disease-related alpha-synuclein pathology
by: Parkkinen, L, et al.
Published: (2013)

Alpha-synuclein oligomers: a new hope.
by: Bengoa-Vergniory, N, et al.
Published: (2017)

Targeting alpha-synuclein as a therapy for Parkinson’s disease
by: Fields, CR, et al.
Published: (2019)

Alpha-synuclein proximity ligation assay (AS-PLA) in brain sections to probe for alpha-synuclein oligomers
by: Roberts, RF, et al.
Published: (2019)

Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models.
by: Sloan, M, et al.
Published: (2012)

An impedimetric assay of alpha-synuclein autoantibodies in early stage Parkinson's disease
by: Xu, Q, et al.
Published: (2014)

Mapping networks of alpha-Synuclein proteostasis in cellular models of Parkinson's disease pathology
by: Lewin, R
Published: (2020)

α-Synuclein and dopamine at the crossroads of Parkinson's disease.
by: Venda, L, et al.
Published: (2010)

Initiation and progression of α-synuclein pathology in Parkinson’s disease
by: Tofaris, GK
Published: (2022)

Detection of alpha-synuclein conformational variants from gastro-intestinal biopsy tissue as a potential biomarker for Parkinson's disease
by: Ruffmann, C, et al.
Published: (2018)

Alpha-synuclein pathology in the olfactory pathways of patients with dementia
by: Hubbard, P, et al.
Published: (2006)

Alpha-synuclein pathology in the olfactory pathways of dementia patients.
by: Hubbard, P, et al.
Published: (2007)

LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model.
by: Alegre-Abarrategui, J, et al.
Published: (2009)

Association of MAPT (tau) haplotype with the pathology of Parkinson's disease
by: Parkkinen, L, et al.
Published: (2013)

Physiological and pathological properties of alpha-synuclein.
by: Tofaris, G, et al.
Published: (2007)

UNDERSTANDING THE EARLY PATHOLOGICAL PATHWAYS IN PARKINSON'S DISEASE. THE OXFORD PARKINSON'S DISEASE CENTRE
by: Hu, M, et al.
Published: (2010)

The role of alpha-synuclein oligomers in Parkinson's disease pathophysiology and biology
by: Roberts, R
Published: (2015)

Macroautophagy, alpha-synuclein and dopamine neurotransmission: implications for Parkinson’s disease
by: Hunn, BHM
Published: (2017)

Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease
by: Parkkinen, L, et al.
Published: (2003)

Nanobodies as allosteric modulators of Parkinson’s disease–associated LRRK2
by: Singh, Ranjan K, et al.
Published: (2023)

Dysregulation of dopamine metabolism in LRRK2-associated Parkinson's disease.
by: Chan, Clarice Zi Ying.
Published: (2013)

The study of dopamine metabolism with LRRK2 variants in Parkinson’s disease
by: Kwok, Wei Hao
Published: (2015)

The significance of α-Synuclein, Amyloid-β and Tau pathologies in Parkinson's disease progression and related dementia
by: Compta, Y, et al.
Published: (2013)

REST protects dopaminergic neurons from mitochondrial and α-synuclein oligomer pathology in an alpha synuclein overexpressing BAC-transgenic mouse model
by: Ryan, BJ, et al.
Published: (2021)

Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons
by: Zambon, F, et al.
Published: (2019)

Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia
by: Parkkinen, L, et al.
Published: (2004)

Understanding the role of LRRK2 in protein translation - implications for Parkinson's disease.
by: Cheng, Yue Xiang.
Published: (2010)

Characterization of novel neuroprotective ligands modulating molecular behavior of alpha synuclein in Parkinson's disease
by: Toh, Hui Ting
Published: (2014)

The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.
by: Zarranz, J, et al.
Published: (2004)

Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies
by: Parkkinen, L, et al.
Published: (2016)

Coexisting pathologies in the brain: influence of vascular disease and Parkinson's disease on Alzheimer's pathology in the hippocampus.
by: Smith, M, et al.
Published: (2000)

The Parkinson’s disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability
by: Hallacli, Erinc, et al.
Published: (2022)

Molecular and behavioural characterisation of novel alpha-synuclein BAC transgenic mouse models of Parkinson's disease
by: Janezic, S
Published: (2013)

Alpha-synuclein in Parkinson's disease: molecular pathogenesis and development of genome engineering-based silencing approaches
by: Heman-Ackah, S
Published: (2015)

α-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease.
by: Ryan, B, et al.
Published: (2014)

Assessment of α-Synuclein Pathology
by: Alafuzoff, I, et al.
Published: (2008)

Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein.
by: Senior, S, et al.
Published: (2008)

Alpha-synuclein dysfunction in Lewy body diseases.
by: Tofaris, G, et al.
Published: (2005)

RNA dysfunction and aggrephagy at the centre of an amyotrophic lateral sclerosis/frontotemporal dementia disease continuum.
by: Thomas, M, et al.
Published: (2013)